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Abstract

Introduction: Fifty percent of women with gestational diabetes mellitus (GDM) may progress to type 2 diabetes
with highest risk among black women. This study aims to characterize postpartum diabetes screening rates
among U.S. women with GDM by racial and ethnic group to characterize potential disparities.
Materials and Methods: A standardized search of Ovid-Medline, Embase, Scopus, Cumulative Index of
Nursing and Allied Health Literature (CINAHL), Cochrane, ProQuest, and Clinicaltrials.gov was conducted
through October 12, 2018. Of 1,555 titles reviewed, 27 studies met inclusion criteria. Meta-proportion routines
with random-effects models estimated pooled postpartum screening proportion effect size (ES) with 95%
confidence interval (CI) by racial and ethnic group. Heterogeneity was measured using Cochrane’s Q and
Higgins I2 tests. Data were stratified by intervention and data source.
Results: There were 96,439 women, of whom 81,930 had race/ethnicity recorded. Heterogeneity was high
(I2 = 99.7%). Postpartum screening rates were low (pooled ES 42% [95% CI 35%–48%]). Point estimates for
pooled screening proportions were lower among white (pooled ES 35% [95% CI 28%–42%]) and black (pooled
ES 33% [95% CI 24%–42%]) women than among Hispanic (pooled ES 45% [95% CI 37%–53%]) and Asian
(pooled ES 50% [95% CI 41%–58%]) women. Interventions to improve screening were most common and
effective among Hispanic women.
Discussion: Postpartum screening for diabetes after GDM remains low, and black women have among the
lowest postpartum screening rates despite highest risk for type 2 diabetes progression. Reporting of race/
ethnicity, screening methods, and screening time frames varied across studies.
Conclusion: Future studies must standardize racial/ethnic data reporting and examine interventions that address
postpartum diabetes screening and prevention.
Keywords: gestational diabetes, race and ethnicity, postpartum diabetes screening, health disparities

Introduction

G

estational diabetes mellitus (GDM) complicates
5%–9% of pregnancies in the United States, and risk
increases with age, body mass index (BMI), nonwhite race,
and lower socioeconomic status.1–4 One third of women with
GDM have persistent glucose abnormalities at 6–12 weeks
postpartum, and more than half may develop type 2 diabetes

during their lifetime.5–7 Furthermore, the risk of developing
type 2 diabetes appears to be highest among black women.4,8
Thus, GDM is associated with significant risk of future
chronic disease among young women, and postpartum
follow-up is critical.3,5
Type 2 diabetes screening after a pregnancy complicated by GDM is critical because hyperglycemia, even
in a relatively asymptomatic patient, increases the risk for
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complications, such as neuropathy, retinopathy, and nephropathy.9,10 Furthermore, impaired glucose metabolism increases
risk of maternal obstetric and child developmental complications in future pregnancies.5 With early detection of at risk
patients, lifestyle interventions and metformin can reduce the
risk for progression to type 2 diabetes by 50%.11–13
The American College of Obstetricians and Gynecologists
and the American Diabetes Association recommend diabetes
screening at 4–12 weeks postpartum and every 1–3 years
thereafter among women with GDM.3,5 Fasting plasma glucose and the 2 hours 75 g oral glucose tolerance test (oGTT)
are acceptable tests in the 4–12 weeks postpartum, but the
oGTT is most sensitive. A hemoglobin A1C (Hb A1C) is acceptable for screening after 12 weeks postpartum.
However, estimates from prior studies suggest that rates of
screening are low, particularly in populations served by
Medicaid.14–17 A prior systematic review, including single
center studies and a single large prospective cohort study,
estimated median postpartum screening rates to be 48%
(range 34%–73%).14 Race was mentioned as one of many
factors that could affect screening rates, but this variation was
not systematically examined. In women on Medicaid during
pregnancy, receipt of recommended screening appears to be
under 10% in the first 12 weeks and under 20% at 1 year.15,17
Systematic reviews and meta-analyses quantify the rates of
progression to type 2 diabetes from GDM7,18 as well as the
recurrence of GDM.19 The utility of reminder systems for
screening after pregnancy is well documented20,21 as is the
sensitivity and specificity of different tests for screening.22,23
Another systematic review in 2013 stratified studies by
screening time frame and active intervention compared to
usual care, but again did not look specifically at variation by
race/ethnicity.24 Thus, while screening rates and strategies to
improve screening have been documented, there has not been
a systematic examination to date of screening rates and interventions to improve screening across racial and ethnic
groups which is critical for addressing health disparities.25
In the current systematic review, we expand upon existing
reviews to include studies published after 2013, incorporating one large retrospective cohort study and several other
smaller studies, with a specific aim to describe racial and
ethnic differences in screening rates. To accomplish this
unique objective, we selected studies that specifically reported screening rates by racial and ethnic group, and we
utilized meta-analysis techniques to determine how postpartum diabetes screening rates vary by race/ethnicity among
women with a history of GDM in the United States.
Materials and Methods

This systematic review was registered on March 7, 2017 in
PROSPERO (CRD42017068383). The search strategy was
intentionally broad seeking to capture all literature that addressed any postpartum diabetes screening in women with
GDM. The initial search was not limited to studies that addressed U.S. populations or racial and ethnic disparities because there were concerns that this would eliminate studies
with race data in the full text that were not highlighted in titles
and abstracts. Prospective and retrospective cohort studies,
cross-sectional studies, case–control studies, and randomized
controlled trials were considered for inclusion. Case reports,
case series, and abstracts were excluded.

HERRICK ET AL.

Published and gray literature was searched using strategies
designed by a medical librarian for the concepts of GDM
and postpartum diabetes screening. These strategies were established using a combination of standardized terms and
keywords, and were executed in Ovid Medline 1946-, Embase
1947-, Scopus 1823-, Cumulative Index of Nursing and Allied
Health Literature (CINAHL) 1937-, Cochrane Database of
Systematic Reviews, Cochrane Register of Controlled Trials,
Database of Abstracts of Reviews of Effects, ProQuest Dissertations and Theses, and Clinicaltrials.gov. Databasesupplied English language limits were applied.
Search terms included variations and combinations of the
following terms: gestational diabetes, pregnancy-induced
diabetes, pregnancy diabetes, diabetes mellitus gravidarum,
postpartum period, puerperium, puerperal, postdelivery,
postnatal, glucose tolerance test, fasting plasma glucose, oral
glucose tolerance, glycemic, HbA1C, A1C, and hemoglobin
A1C. Full search strategies for each database are delineated
in Supplementary Data S1. All searches were initially completed in February 2017 and updated in October 2018 with
results exported to EndNote. Automated duplicate finding
was used and 1339 duplicates were assumed to be accurately
identified and removed for a total of 1555 citations. Manual
review of the reference list for each incorporated study was
completed to identify any studies missing from our search
strategy. Institutional Review Board approval was not required for this systematic review and meta-analysis of deidentified published data.
Two authors individually reviewed titles and abstracts
against inclusion and exclusion criteria. Full text articles
were retrieved where necessary to further evaluate relevant
articles for inclusion. As differences by race and ethnicity are
likely unique to each country and this was the focus of our
review, only studies performed in the United States were
included in the final review and meta-analysis. Non-U.S.
studies were excluded at the title and abstract review stage if
it was possible to identify study location. Studies that discussed postpartum screening but did not include sufficiently
stratified publicly available race/ethnicity data were excluded
at the full-text review stage.
Of the 1,555 citations derived with the above search
strategy, a further 298 studies were excluded because they
were animal studies, duplicates, studies on an unrelated topic,
or not in English. The remaining 1,257 abstracts were reviewed and a total of 1,197 studies were excluded because
they were abstract only, case reports, commentaries/errata,
guidelines, reviews, systematic reviews, non-U.S. populationbased studies, qualitative studies, and studies for which no
information on postpartum screening rates was available.
Sixty articles were obtained for full-text review. Additional
studies were excluded because there were no stratified
race/ethnicity data for screening rates or because the same
cohort had been used in a previously included study. Ultimately, 27 articles met inclusion criteria and contributed
data to the analysis.15,26,31,32–51 Three of the studies were
divided into intervention and non-intervention groups in
the meta-analysis.39,41,42 Figure 1 illustrates the PRISMA
diagram for study selection.
Abstracted data included publication year, data collection
time frame, data source (electronic medical record [EMR],
laboratory data warehouse, survey, and administrative
claims), study setting and location, study method, method for
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FIG. 1. Flowchart
depicting selection of studies
included in the systematic
review and meta-analysis,
according to PRISMA
criteria.

identifying GDM, and the time frame for postpartum screening
assessment. In addition, it was noted if an intervention to improve screening was studied and if only recommended
screening tests or all tests were considered. Finally, total
numbers of women with GDM and total numbers of women
with GDM who were screened for diabetes postpartum both
overall and within each racial and ethnic group (white, black,
Hispanic, Asian, and other) were abstracted. To standardize
our data collection, when screening percentages were presented between racial and ethnic groups, we calculated
screening rates within racial and ethnic groups. A template for
data extraction is presented in Supplementary Data S2.
As the exposure of interest for our review, we collected the
method by which race and ethnicity were assessed (selfreport, birth certificate, medical record extraction, geographic variables, or not reported). Studies were examined
for assessment of confounding, and when assessed, incorporated confounders were extracted. Study quality was also
assessed using the 14 question Quality Assessment Tool for
Observational Cohort and Cross-Sectional Studies from the
National Heart, Lung, and Blood Institute (NHLBI) (Supplementary Table S1).
This tool assesses study quality indicators such as prespecification of the research question and population, inclusion
of >50% of eligible participants, utilization of inclusion and
exclusion criteria, and sample size justification. It also considers assessment of exposure before outcome, time frame
sufficient for outcome assessment, exposure and outcome
measurement validity and consistent application, outcome assessor blinding, <20% loss to follow-up, and confounder assessment. Questions on this tool related to exposure dose and
frequency were not applicable to our research question considering race and ethnicity as the exposure.
All analyses were performed using Stata 15.1 (College
Station, TX). A meta-analysis of proportions (routine metaprop) was utilized to combine proportion estimates across

studies and approximate a pooled proportion effect size with
95% confidence interval (CI) for postpartum screening in the
overall population and each racial and ethnic group. The
effect of intervention to improve screening was examined
through stratification of analyses by populations in intervention and nonintervention groups. Stratified analyses are
also presented according to data source (EMR vs. other
[administrative claims, laboratory data warehouse, or survey]). Heterogeneity was assessed using the Cochran’s Q and
Higgins I2 statistic. Given substantial heterogeneity between
studies, a random effects model was appropriate. Publication
bias was assessed utilizing a funnel plot and Begg and Egger’s tests for small study effects. In addition, a sensitivity
analysis was conducted, eliminating studies with under 200
participants.
Results
Study characteristics

The publication dates of the studies included in this systematic review and meta-analysis range from 2006 to 2018,
representing deliveries from 1995 to 2016. Table 1 summarizes study characteristics, including author, year and study
data sources, setting, and location. There were no randomized
controlled studies and most included studies were retrospective cohorts. Studies differed in the way GDM was
identified (Table 1, column 4). In most studies, GDM diagnosis was established by a 3 hours oGTT that met either the
Carpenter-Coustan criteria or National Diabetes Data Group
criteria (NDDG) or by coding from the International Classification of Diseases, 9th Revision (ICD-9). Some studies
used ICD-9 classification combined with medication or test
strip prescription. Other studies only specified medical chart
review or use of procedure codes for prenatal glucose
screening for GDM (CPT 82950 or 82951), and survey
studies utilized self-report to identify GDM.
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Study method

Study setting, State,
Institution, Data source

Retrospective
cohort

Retrospective
cohort

Retrospective
cohort

Retrospective
cohort

Lawrence et al.34

Stasenko et al.40

Blatt et al.27

Hale et al.15

Retrospective
cohort

Cross sectional

Mendez-Figueroa
et al.43

Oza-Frank36,c

McCloskey et al.35 Cross sectional

Prospective
cohort

Ferrara et al.31

Medicaid
SC
Administrative claims,
birth certificate,
hospital discharge data
Academic
MA
Boston Medical Center
EMR – Administrative
claims
Academic
DIP clinic
RI
Brown University
EMR
PRAMS
CO, MN, UT, NYC
Survey

Integrated health system
Northern CA
Kaiser
EMR
Integrated health system
Southern CA
Kaiser
EMR
Academic
Northern CA
UCSF
EMR
Quest Data Warehouse
U.S. National

Studies with no intervention to improve screening
Retrospective
Academic
Kim et al.33
cohort
MI
University of Michigan
EMR
Retrospective
Academic
Russell et al.38
cohort
DIP clinic
RI
Brown University
EMR
26
Retrospective
Academic
Almario et al.
cohort
PA
Thomas Jefferson
University
EMR + Quest, Labcorp
data
Retrospective
Integrated health system
Dietz et al.29
cohort
OR, WA
Kaiser NW
EMR

Author
(publication year)

Postpartum screening
time frame and test(s)

Self-report

3 hours oGTT (C/C)

ICD9

ICD9 for GDM +
CPT code for
oGTT in
pregnancy

2 hours oGTT
(IADPSG)

3 hours oGTT (C/C)

3 hours oGTT (C/C)

£12 weeks
2 hours oGTT, FPG

FPG ‡126 or 1 hour
GCT ‡200 or 3
hours oGTT
(NDDG), or ICD-9
+ insulin or
glyburide
3 hours oGTT
(NDDG)

<4 months
NR

8–159 days
2 hours oGTT

6 months
2 hours oGTT, FPG, Hb A1C

6 months
2 hours oGTT, 3 hours
oGTT, FPG, RPG, Hb A1C
5–13 weeks
2 hours oGTT, FPG, RPG

6 months
2 hours oGTT or FPG

7 days to 6 months
2 hours oGTT or FPG

6 weeks to 12 months
2 hours oGTT, FPG, Hb A1C
after 12 weeks

5–12 weeks
2 hours oGTT, FPG

3 hours oGTT (C/C)
+ clinician dx

ICD9 code + Chart
‡6 weeks
review +5% check Any labs with glucose,
of 3 hours oGTT
Hb A1C, FPG, oGTT
(C/C)
3 hours oGTT (C/C) After delivery
5–8.5 weeks IQR
2 hours oGTT, FPG

GDM identification

5,524/14,448 (38)

251/356 (71)

NR

NR

333/415 (80)

5,144/6,239 (83)

NR

NR

402/829 (48)

201/414 (49)

97/415 (23)

214/6,239 (3)

4,486/23,299 (19)

251/745 (34)

11,164/11,825 (94) 5,939/11,825 (50)

NR

356/356 (100)

18/90 (20)

156/344 (45)

265/344 (77)

90/90 (100)

204/533 (38)

N = 96,439

Overall postpartum
diabetes screening
n (%)

447/533 (84)

Women with at
least 1 visit after
delivery n (%)

47/58 (81)

3/10 (30)

64/139 (46)

NR

Hispanic
n = 18,336

(51)

32/100 (32)

5/30 (17)

102/2,949 (3)

18/101 (18)

(55)

27/53 (51)

(43)

83/162 (51)

12/52 (23)

NR

NR

40/62 (65)

4/48 (8)

NR

244/1,272 (19)

146/338 (43)

3,139/6,144 (51) 1,333/2,259 (59)

70/274 (26)

98/2,949 (3)

75/89 (84)

6/22 (27)

NR

NR

Asian
n = 12,269

1,497/3,692 (41) 1,729/3,799 (46)

16/56 (29)

219/804
(27)

177/677
(26)

6/8 (75)

5/29 (17)

37/69 (54)

31/60 (52)

Black
n = 7,315

774/5,236 (15) 209/1,291 (16) 393/2,209 (18)

66/238 (28)

1,184/2,484 (48)

1,547/4,652 (33)

122/196 (62)

4/29 (14)

37/99 (37)

159/439 (36)

White
n = 36,807

Postpartum diabetes screening by race/ethnicity n (%)a

Table 1. Summary of Studies Included in the Systematic Review and Meta-Analysis
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(continued)

(51)

19/36 (53)

NR

12/276 (4)

125/663 (19)

NR

64/134 (48)

309/737 (42)

1/4 (25)

NR

18/37 (49)

14/34 (41)

Other
n = 7,203b
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Retrospective
cohort

Study method

Study setting, State,
Institution, Data source
GDM identification

Medical group
ICD9 + 3 hours
MA
oGTT or test strip
Harvard Vanguard
script
EMR
30
Retrospective
Private health plan
ICD9 (1 inpatient or
Eggleston et al.
cohort
U.S. National
2 outpatient)
Administrative claims
51
Retrospective
Academic
Rosenthal et al.
3 hours oGTT (C/C)
cohort
DIP clinic
or clinician dx
MA
Brigham & Womens
EMR
Retrospective
Academic
NR
Battarbee and
case-control
IL
Yee44
Northwestern EMR
Cross sectional
PRAMS
Self-report
Jones et al.47
CO, MA
Survey
Retrospective
Academic
Rosenbloom
3 hours oGTT (C/C)
cohort
MD
et al.48
University of Maryland
EMR
Prospective
Academic
3 hours oGTT (C/C)
Werner et al.49
cohort
RI
or GCT ‡200
Brown University
EMR
Studies with intervention to improve screening with a non-intervention ‘‘control’’
42
Retrospective
FQHC
NR
Cahill et al.
cohort
NJ
(historical
EMR
control)
Prospective
cohort
intervention:
nurse
counseling 1
session
41
Retrospective
Academic
3 hours oGTT (C/C)
Stasenko et al.
cohort
Northern CA
(historical
UCSF
control)
EMR
Retrospective
cohort
intervention:
CDE
counseling 1
session—with
verbal and
written
information

Paez et al.37

Author
(publication year)

6 months
2 hours oGTT or FPG

187/560 (33)

129/245 (53)

NR

NR

48/64 (75)

55/64 (86)

126/300 (42)

7/74 (9)

258/300 (86)

12 weeks
2 hours oGTT

16/118 (14)

313/584 (54)

279/683 (41)

52/71 (70)

98/118 (83)

‡6 weeks
2 hours oGTT

Before postpartum visit
2 hours oGTT, FPG

NR

560/683 (82)

<4 months
NR

4 months
2 hours oGTT

36/68 (53)

48/173 (28)

NA

NA

84/214 (39)

NR/36

109/222 (49)

60/164 (37)

41/122 (34)

4,252/19,161 (22)

26,125/32,253 (81) 7,722/32,253 (24)
12 months
Any labs with glucose
2 hours oGTT, FPG, Hb A1C
6–12 weeks
296/404 (73)
155/404 (38)
2 hours oGTT

White
n = 36,807

10/22 (45)

7/68 (10)

33/50 (66)

2/12 (17)

13/46 (28)

NA

NA

NR

Hispanic
n = 18,336

27/29 (93)

Asian
n = 12,269

12/14 (86)

Other
n = 7,203b

18/36 (50)

11/76 (14)

48/64 (75)

7/74 (9)

17/50 (34)

NR

93/191 (49)

70/181 (39)

NR

71/121 (59)

111/256 (43)

NA

NA

10/23 (43)

NR/7

68/100 (68)

43/74 (58)

NR

(continued)

NR

NR

NA

NA

5/14 (36)

NR/7

10/21 (48)

48/115 (42)

114/282 (40)

1,039/4,086 (25) 1,219/3,743 (33) 1,061/4,588 (23)

58/149 (39)

NR

126/597
(21)

14/20 (70)

Black
n = 7,315

Postpartum diabetes screening by race/ethnicity n (%)a

63/74 (85)

NR

N = 96,439

Overall postpartum
diabetes screening
n (%)

118/139 (85)

‡6 weeks
2 hours oGTT, FPG; Hb A1C
after 12 weeks

Postpartum screening
time frame and test(s)

Women with at
least 1 visit after
delivery n (%)

Table 1. (Continued)
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Study method

Study setting, State,
Institution, Data source
GDM identification

NR

NR

NR

43/48 (74)

6–12 weeks
2 hours oGTT

6–12 weeks
2 hours oGTT

6–12 weeks
2 hours oGTT

31/58 (53)

35/80 (44)

49/106 (46)

20/67 (30)

400/707 (57)

168/203 (83)

187/203 (92)

NR

156/257 (61)

N = 96,439

220/257 (86)

6 weeks
2 hours oGTT – FSBS
4 · /day · 2 days

4–12 weeks
2 hours oGTT, FPG

NR
2 hours oGTT

Postpartum screening
time frame and test(s)

Overall postpartum
diabetes screening
n (%)

13/26 (50)

9/28 (32)

19/39 (49)

9/28 (32)

NR

NR

NR

White
n = 36,807

14/26 (54)

2/13 (15)

14/39 (36)

1/3 (33)

NR

NR

NR

Black
n = 7,315

5/5 (100)

14/24 (58)

5/7 (71)

1/4 (25)

376/648 (58)

168/203 (83)

87/120 (73)

Hispanic
n = 18,336

NR

9/14 (64)

6/8 (75)

0/5 (0)

NR

NR

NR

Asian
n = 12,269

Postpartum diabetes screening by race/ethnicity n (%)a

4/6 (67)

1/1 (100)

5/15 (33)

8/23 (35)

24/59 (41)

NR

69/137 (50)

Other
n = 7,203b

b

Not all studies had race/ethnicity data on the whole population. The sum of women with GDM in all race/ethnicity groups does not always equal the total women with GDM.
Individuals represented in the ‘‘Other’’ group are indicated here exactly as they are reported in each study. For studies where rates were not reported for white, black, Hispanic and Asian populations, this ‘‘Other’’ category could include some of these
groups.
c
Number of individuals (total and screened) in each ethnic/racial group were not reported in this study; only percentages were reported.
C/C, Carpenter and Coustan criteria; CPT, Current Procedural Terminology; DIP, Diabetes in Pregnancy Specialty clinic; EMR, Electronic Medical Record; FPG, fasting plasma glucose; FQHC, Federally Qualified Health Center; FSBS, finger stick
blood sugar; GCT, glucose challenge test; GDM, gestational diabetes mellitus; Hb A1C, hemoglobin A1C; IADPSG, International Association of Diabetes and Pregnancy Study Groups; ICD9, International Classification of Diseases, 9th edition; IQR,
interquartile range; NA, not applicable; NDDG, National Diabetes Data Group; NR, not reported; oGTT, oral glucose tolerance test; PRAMS, Pregnancy Risk Assessment Monitoring System; RPG, random plasma glucose.

a

Schellinger et al.39 Retrospective
County hospital
NR
cohort
Midwest
(control)
EMR
Retrospective
cohort
intervention:
Centeringª
Pregnancy 4
sessions with
one on
postpartum
risk
Studies with intervention to improve screening without a non-intervention ‘‘control’’
Prospective
Academic
Hunt et al.32
3 hours oGTT (C/C)
cohort
TX
intervention:
UT-San Antonio
nurse case
EMR
manager three
contacts
Prospective
Private practice
NR
Carson et al.28
cohort
NJ
intervention:
EMR
home
fingerstick
testing
50
Prospective
Academic
3 hours oGTT (C/C)
Werner et al.
cohort
MD, RI
or GCT ‡200
intervention:
Johns Hopkins
reminder calls Brown University
EMR
Prospective
Academic
3 hours oGTT (C/C)
Dinglas et al.46
cohort
NY
or GCT ‡200
intervention:
NYU-Winthrop
reminder calls EMR
Prospective
Academic
3 hours oGTT
Carter et al.45
cohort
MO
(NDDG) or GCT
intervention:
Washington University in
‡200
reminder calls
St. Louis
EMR

Author
(publication year)

Women with at
least 1 visit after
delivery n (%)

Table 1. (Continued)
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Table 2. Pooled Estimates of Postpartum Diabetes Screening by Race and Ethnicity
from Metaproportion Routines
Sensitivity analysis (Studies with
total samples size >200 participants)

Overall

Totala
White
Black
Hispanic
Asian
Otherb

Included
studies

No. of women
with GDM

27
22
22
21
17
12

96,439
36,807
7,315
18,336
12,269
6,351

Pooled proportion
point estimate
of postpartum
screening ES (95% CI)
0.42
0.35
0.33
0.45
0.50
0.36

(0.35–0.48)
(0.28–0.42)
(0.24–0.42)
(0.37–0.53)
(0.41–0.58)
(0.27–0.45)

Included
studies

No. of
women
with GDM

19
16
15
15
12
9

95,643
36,547
7,117
18,148
12,184
6,312

Pooled proportion
point estimate
of postpartum
screening ES (95% CI)
0.42
0.33
0.33
0.44
0.48
0.36

(0.35–0.50)
(0.25–0.40)
(0.23–0.44)
(0.36–0.52)
(0.39–0.57)
(0.27–0.46)

Downloaded by Washington Univ from www.liebertpub.com at 09/10/20. For personal use only.

a

Oza-Frank36 was only included in the total. Although screening rates were reported for racial and ethnic groups, exact numbers to
calculate screening rate were only reported on the total.
b
Studies included in the meta-analysis of proportions for the ‘‘Other’’ racial and ethnic group must have specified screening rates for all
four racial and ethnic groups (white, black, Hispanic, and Asian), such that the ‘‘Other’’ group would not include information about
screening in any of these groups. There were 10 studies that had data for an ‘‘Other’’ group (including a total of 852 women) that did not
have data stratified for all white, black, Hispanic, and Asian populations as well and are not included in the meta-analysis here. This
discrepancy accounts for the 1% of the population not represented in this table.
CI, confidence interval; ES, effect size.

In addition to identifying GDM in different ways, studies
included in the meta-analysis also differed regarding size of
the population with GDM. The total number of women with
GDM in the studies included in our meta-analysis was
96,439. Race and ethnicity data were available on 81,930 of
these women. Study populations ranged from 58 to 32,253
women with GDM. Nineteen studies did not include an intervention,15,26,27,29–31,33–38,40,43,44,47–49,51 five had only an
intervention arm,28,32,45,46,50 and three studies had both
nonintervention and intervention arms.39,41,42 Interventions
varied and included nurse education,41,42 reminder
calls,45,46,50 home glucose testing,28 nurse case management,32 and Centering Pregnancyª group prenatal care.39
Two studies in the meta-analysis utilized claims data,15,30
one study used a large laboratory data warehouse,27 two
studies utilized national survey data,36,47 and others used
EMR data from single, predominantly academic, medical
centers, or integrated health systems (Table 1, column 3).
Four studies had only privately insured patients,28–31 one had
Medicaid only15 and others had a mix of payer sources or
failed to report this variable. Maternal age, parity, insurance
status, education, BMI, postpartum visits, and diabetes
medication use in pregnancy were commonly collected
confounders among the included studies. Among the studies
that reported attendance at the postpartum visit, all reported
attendance rates ‡70% (Table 1, column 6).
Study quality as assessed by the NHLBI quality assessment tool was generally fair to good. All studies had
defined the research question, specified the population
under study, clearly applied inclusion and exclusion criteria, and had exposure assessed before outcome (for
noncross-sectional studies). While all studies collected at
least some demographic and clinical information that
could be considered confounders, six studies did not include a method, such as multivariable regression, to directly assess the effect of confounders on the screening
outcome.28,32,42,45,46,50 Four studies had <50% of the eligible population participating27,37,43,46 and three did not

specify how many women were eligible.42,45,50 Loss to
follow-up was <20% in 11 of the 24 studies that were not
cross-sectional.15,26,29,30,33,34,37,39,44,48,49 Only five studies did an a priori sample size calculation,38,43,45,46,49 and
assessors were not blinded to outcome in any study. Only
two studies included a self-reported postpartum screening
outcome.36,47 All other outcomes were laboratory results
documented in medical records or administrative codes for
laboratories completed. Race and ethnicity were typically
self-reported or extracted from birth certificate or medical
records. One study utilized a method to estimate racial and
ethnic distribution in the sample through geographic information systems,30 and four studies did not record how
race and ethnicity were assessed.27,36,37,51
Findings

Overall, postpartum screening rates for diabetes after a
pregnancy complicated by GDM were low. As shown in
Table 2, the pooled proportion estimate of screening among
all women with GDM was 42% (95% CI 35%–48%).
Screening rates were relatively low among individual racial
and ethnic groups as well. The overall pooled proportion
estimates of screening among different racial and ethnic
groups follow: white 35% (95% CI 28%–42%), black 33%
(95% CI 24%–42%), Hispanic 45% (95% CI 37%–53%),
Asian 50% (95% CI 41%–58%), and other 36% (95% CI
27%–45%) (Table 2). Point estimates for screening were at
least 10% higher in Asian and Hispanic populations than in
white and black populations, although CIs overlapped.
Studies in which there was an intervention to improve
screening reported higher pooled proportions screened 56%
(95% CI 44%–66%) than those without intervention 37%
(95% CI 30%–44%) (Fig. 2). When data were stratified by
intervention and no intervention, only Hispanic women demonstrated a significant effect of intervention on pooled proportion estimates of screening (intervention 68% [95% CI 54%–
81%] vs. nonintervention groups 37% [95% CI 29%–45%]).
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FIG. 2. Forest plots depicting pooled proportions for postpartum diabetes screening in each racial and ethnic group (A:
Total, B: White, C: Black, D: Hispanic, E: Asian, F: Other Race), stratified by no intervention versus intervention.
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FIG. 3. Forest plots depicting pooled proportions for postpartum diabetes screening in each racial and ethnic group (A:
Total, B: White, C: Black, D: Hispanic, E: Asian, F: Other Race), stratified by data source (EMR vs. other [administrative
claims, laboratory data warehouse, or survey data]). EMR, Electronic Medical Record.
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There were also more studies reporting on interventions in
Hispanic women than any other group (eight intervention
studies among Hispanic women,28,32,39,41,42,45,46,50 five for
white and black women,28,41,45,46,50 four for Asian women,28,41,46,50 and three for other racial and ethnic groups).28,46,50
Other racial and ethnic subgroups did not demonstrate consistent effects of intervention on screening. Studies with interventions to improve screening are reported in Table 1 with
information about type of intervention and screening point
estimates by racial and ethnic group. A meta-analysis of intervention effect in the three studies with a control arm was not
possible given heterogeneity. Stratification by study quality,
study design, method for identifying GDM, or screening
time frame did not result in differences in pooled proportion
screened overall or in any racial and ethnic subgroup.
Overall, studies using the EMR as the data source had a
pooled proportion of women screened of 45% (95% CI 40%–
50%) compared with 27% (95% CI 17%–38%) in studies
using other data sources (administrative claims, laboratory
data warehouse, survey). As these CIs do not overlap, it can
be concluded that this is a statistically significant difference. Significant differences between screening rates by data
source were present for white, Hispanic, and other racial and
ethnic groups (Fig. 3).
Heterogeneity and publication bias are important considerations when assessing the validity of our findings. The I2 value
generated for the total population is quite high at 99.7%, indicating that the variability in results is attributable to variation
between studies. The same was true of the I2 for each racial and
ethnic group. With stratification by intervention versus nonintervention, heterogeneity was lower in the intervention stratum
among racial and ethnic subgroups (31%–88%). Visual inspection of a funnel plot was largely symmetrical implying low
risk of publication bias (Supplementary Fig. 1). Begg and
Egger’s tests also demonstrated no small study effects. In a
sensitivity analysis including only studies with 200 or more
participants, pooled proportion estimates for screening were
not appreciably different overall or in each racial and ethnic
group (Table 2).15,27,29–36,38–41,43,44,47,49,51
Discussion

Postpartum screening rates for type 2 diabetes in a population of women with a history of GDM are low among all
racial and ethnic groups. Guidelines recommend that women
should be screened at multiple intervals after a pregnancy
with GDM, and less than half of women in reported studies
are being screened. There were also very few studies incorporating black women in interventions intended to improve
screening rates. Overall, black women were screened at lower
rates than Hispanic and Asian women and similar rates to
non-Hispanic white women. This disparity must be addressed
in future studies, particularly as black women are at highest
risk for progression to type 2 diabetes after a pregnancy with
GDM.4,8 In addition, disproportionate maternal mortality and
morbidity among black women in the United States is a
critical public health problem, highlighting the need for
particular focus on care for this population during and after
pregnancy.52
Hispanic women also have a high risk for progression to
type 2 diabetes after pregnancy with GDM, and more studies
have been conducted utilizing interventions to improve
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screening among Hispanic women than any other racial and
ethnic group. These interventions, particularly higher intensity interventions like Centering Pregnancyª, significantly
increased screening among Hispanic women and should be
implemented and studied at larger scale and among other
racial and ethnic groups.32,39,42
To our knowledge, this is the first systematic review to
specifically examine racial and ethnic variation in postpartum
diabetes screening rates. In addition, our analysis is unique in
that metaproportion routines were utilized to estimate pooled
proportion estimates. CIs overlapped; however, point estimates for pooled screening rates were at least 10% higher
among Asian and Hispanic women than among white and
black women. There were a larger number of studies with
interventions to improve screening among Hispanic women,
and when point estimates for pooled screening proportions
were compared among nonintervention groups, these estimates were similar for white, black, and Hispanic women.
Nonetheless, even in nonintervention groups, the point estimate for postpartum screening among Asian women was
about 10% higher. It is important to recognize both the low
overall screening rates and this discrepancy by race and
ethnicity as black and Hispanic women are the most likely to
progress to type 2 diabetes after GDM.
Our study addresses variation in screening rates reported
utilizing different data sources. Studies reporting screening
rates from EMR data had pooled proportions for screening
that were statistically significantly higher than studies using
administrative claims, laboratory data warehouse, or survey
data. While this is understandable given the more detailed
nature of the EMR and ability to access laboratory results, it is
difficult to capture this type of data on the state or national
level in the United States as medical record systems vary
across clinics and hospital systems. Hence, EMR data reflect
screening rates in single, often academic, centers and integrated health systems. With advances in information technology and the establishment of practice-based research
networks, future research can focus on connecting EMR
systems to capture more accurate screening data across multiple systems in routine care. In addition, future research may
focus on development and evaluation of EMR-based interventions aimed at improving diabetes screening rates as well.
This systematic review and meta-analysis has a number of
limitations. There was substantial heterogeneity among studies.
Sources of heterogeneity may include different study designs
and incorporation of interventions to improve screening, study
quality, data sources, race/ethnicity classification, time frame,
and test used for postpartum screening. We felt it was important
to report a pooled screening estimate, despite heterogeneity, to
demonstrate in a rigorous way, across many different studies,
that screening rates are low across all racial and ethnic groups.
Reporting pooled estimates with recognition of heterogeneity
among studies can motivate standardization of future randomized studies in this field. Utilizing stratification and metaregression, the heterogeneity was not consistently explained by
data source, intervention, use of a recommended test, method
for identifying GDM, study quality, study design, or screening
time frame.
In addition, a large number of studies were eliminated at
the full text review stage because they did not present
screening rates stratified by racial and ethnic group. This may
have been related to low numbers of underrepresented
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minorities or inconsistent reporting of screening rates. Some
of these excluded studies controlled for race and ethnicity in
multivariable regression models assessing associations with
screening, but this was typically done using a dichotomous
race variable (e.g., white vs. nonwhite). Future research should
incorporate screening data by race and ethnicity in an easily
accessible manner, particularly as the National Institutes of
Health increases the focus on rigor and reproducibility.
Additional challenges were associated with data collection/reporting and definitions of key variables. Studies
varied in the way race and ethnicity were defined (selfreport, medical record extraction, birth certificate records,
and geographic estimates), and some studies did not report
how race and ethnicity were collected. There was a lack of
consistency among studies in reporting of data for racial/ethnic groups. Some studies reported specific screening
on 4–5 groups (white, black, Hispanic, Asian, and other),
while other studies incorporated only one group and still
others divided data into white and nonwhite populations.
For the purposes of reporting pooled proportions, we only
reported pooled proportions for the ‘‘Other’’ racial/ethnic
category if the study included specific screening rates on
white, black, Hispanic, and Asian populations, so as to limit
the inadvertent inclusion of these racial and ethnic groups in
the ‘‘Other’’ category.
In addition, both GDM diagnosis and outcome definition
varied among studies. Addressing the outcome of postpartum
screening specifically, studies varied regarding the time
frame of postpartum screening as well as the type of testing
completed. While a minority of studies had <50% of the
eligible population participating, many had >20% loss to
follow-up, contributing to the possibility for selection and
ascertainment bias. In addition, studies did not report differences in attendance of the postpartum office visit stratified
by race/ethnicity so this could contribute to differences in
reported screening rates among racial and ethnic groups.
However, the overall percent of women attending at least
one postpartum visit was much higher than the percent of
women with postpartum diabetes screening, so postpartum
visit attendance likely explains only a small amount of this
variation.
Despite the challenges and limitations of this current systematic review and meta-analysis, it highlights the need for
additional research that can have a meaningful impact. Women often utilize their obstetrician and gynecologist for primary care in the childbearing years, hence, these health care
providers are frequently the first-line for postpartum diabetes
screening in the first 12 weeks and 1 year postpartum. Our
study serves as a call to action for researchers and clinicians
to work toward addressing barriers to postpartum diabetes
screening among all women.
Conclusion

Our findings are consistent with previous work that has
demonstrated low rates of postpartum diabetes screening
overall. Greater effort must be directed toward standardizing
the measurement, collection, and reporting of racial and
ethnic data in screening studies. Given the low screening
rates documented among all racial and ethnic groups, and the
high burden of subsequent type 2 diabetes and its complications, well-designed studies to examine interventions that
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comprehensively address the needs of women in the postpartum period are urgently needed. Increasing postpartum
screening for diabetes and enhancing prevention of type 2
diabetes among high risk women are essential next steps to
achieving health equity.
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